ResApp Health Limited (ASX: RAP) is pleased to announce the appointment of Dr Roger Aston as Non-Executive Chairman of the company. Dr Aston replaces Mr Adam Sierakowski who remains on the board as a Non-Executive Director. Dr Aston is both a scientist and a seasoned biotechnology entrepreneur, with a successful track record in both fields. He currently has several executive and non-executive board positions with prominent ASX listed biotechnology companies.
“It is an opportunity and a pleasure to accept this appointment with a company that has the potential to be the leading digital healthcare company in Australia. ResApp is poised to meet a significant need in the fast-growing telehealth sector where-by accurate diagnosis of respiratory illness can be facilitated through the internet,” Dr Aston commented.
“We welcome the appointment of Roger as Chairman and thank Adam for his capable stewardship as we negotiated the transition from Narhex Life Sciences to ResApp Health,” said Dr Tony Keating, Managing Director and CEO. “The board and I look forward to working with Roger and benefiting from his thirty four years’ experience in the biotechnology industry as we strive to commercialise our unique and innovative technology in the exciting and growing field of digital healthcare.”
ResApp has been active in recent months having presented at significant digital healthcare and biotechnology conferences. This weekend, Dr Keating will be presenting ResApp at the Bioshares Biotech Summit in Queenstown, an annual event organised by Australia’s leading independent biotech investment publication. On Wednesday the 29th of July, Dr Keating will be presenting ResApp at the Investing in Digital Health Workshop in Sydney, organised by Ausbiotech, Australia’s biotechnology industry association.
About ResApp Health Limited
Founded in 2014, ResApp Health Limited, through an exclusive license it has been granted by the University of Queensland (UQ) is developing smartphone medical application for the diagnosis and management of respiratory disease. The technology is based on a machine-learning algorithm that uses sound alone without the need for additional hardware to diagnose and measure the severity of a respiratory condition. The algorithm has been successfully tested for pneumonia and asthma diagnosis in clinical proof of concept study by UQ through funding from the Bill and Melinda Gates Foundation.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.